Surface modification of nanostructure lipid carrier (NLC) by oleoyl-quaternized-chitosan as a mucoadhesive nanocarrier

Colloids Surf B Biointerfaces. 2017 Jan 1:149:301-311. doi: 10.1016/j.colsurfb.2016.09.049. Epub 2016 Sep 29.

Abstract

A nanostructure lipid carrier (NLC) composed of solid, and liquid lipid as a core has been developed as a delivery system for hydrophobic drug molecules. The aim of this research was to fabricate an oleoyl-quaternized-chitosan (CS)-coated NLC, where the mucoadhesive property of nanoparticles is enhanced for more efficient drug delivery. NLC loaded with alpha-mangostin (AP), a model hydrophobic drug, were fabricated using a high pressure homogenization process and subsequently coated with CS. The fabricated nanoparticles showed particle sizes in the range of 200-400nm, with low polydispersity, high physical stability and excellent encapsulation efficiency (EE>90%). Additionally, in vitro viability, cytotoxicity and ability of NLC and CS-NLC to affect apoptosis in carcinoma Caco-2 cells were determined using the Triplex assay. Gene expressiom analysis were performed using quantitative reverse transcription Polymerase Chain Reaction (RT-qPCR). Moreover, in vivo toxicological testing of NLCs was conducted in zebrafish embryos. Results indicated that CS-NLC provieded high cytotoxicity than NLC itself. In the case of AP loaded nanoparticles, NLC loaded with AP (AP-NLC), and CS-NLC loaded with AP (CS-AP-NLC) exhibited higher cytotoxicity to Caco-2 over Hela cells. These results indicate that CS-NLC shows enhanced cellular uptake but increased cytotoxicity characteristics over NLC and therefore careful optimization of dosage and loading levels in CS-NLC is needed to allow cancer cell targeting, and for exploiting the potential of these systems in cancer therapy.

Keywords: Alpha-mangostin; Mucoadhesive; Nanostructure lipid carrier; Oleoyl-quaternized-chitosan.

MeSH terms

  • Apoptosis / drug effects
  • Caco-2 Cells
  • Cell Survival / drug effects
  • Chitosan / analogs & derivatives*
  • Cyclin D1 / genetics
  • Cyclin D1 / metabolism
  • Cyclin-Dependent Kinase 4 / genetics
  • Cyclin-Dependent Kinase 4 / metabolism
  • Drug Carriers*
  • Drug Compounding
  • Drug Liberation
  • Gene Expression / drug effects
  • HeLa Cells
  • Humans
  • Hydrophobic and Hydrophilic Interactions
  • Nanoparticles / chemistry*
  • Nanoparticles / ultrastructure
  • Particle Size
  • Protein Kinase Inhibitors / chemistry
  • Protein Kinase Inhibitors / pharmacology*
  • Proto-Oncogene Proteins c-bcl-2 / genetics
  • Proto-Oncogene Proteins c-bcl-2 / metabolism
  • Surface Properties
  • Xanthones / chemistry
  • Xanthones / pharmacology*
  • bcl-2-Associated X Protein / genetics
  • bcl-2-Associated X Protein / metabolism
  • bcl-X Protein / genetics
  • bcl-X Protein / metabolism

Substances

  • BAX protein, human
  • BCL2 protein, human
  • BCL2L1 protein, human
  • CCND1 protein, human
  • Drug Carriers
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins c-bcl-2
  • Xanthones
  • bcl-2-Associated X Protein
  • bcl-X Protein
  • Cyclin D1
  • Chitosan
  • CDK4 protein, human
  • Cyclin-Dependent Kinase 4
  • mangostin